Surf Bio Analysis: $16M Raised
What is Surf Bio?
Surf Bio is a preclinical biopharmaceutical company founded in 2021, focusing on transforming the delivery of antibodies and biologics. Their proprietary Surf SnapShot technology enables high concentrations of monoclonal antibodies for rapid subcutaneous delivery, improving patient accessibility and dosing intervals. The company aims to address therapeutic areas including Diabetes, Oncology, HIV, and COVID-19.
Location
Palo Alto, United States
Employees
1-10
Founded
2021
Funding Status
Seed
Product Features & Capabilities
- Surf SnapShot technology for biologics delivery
- High-concentration monoclonal antibody formulations
- Subcutaneous injection systems
- Proprietary polymer excipients for drug stabilization
Use Cases
Administer monoclonal antibodies in seconds instead of hours; Enable at-home self-administration for patients; Increase dosing intervals with higher concentrations; Collaborate with pharmaceutical companies for product pipelines; Develop formulations for diabetes and oncology therapies
Other Considerations
Raised $16 million in Series Seed financing; Established partnerships with leading pharmaceutical companies; Demonstrated in-vitro and in-vivo safety and efficacy data; Team includes industry veterans from Bigfoot Biomedical and Mode AGC
See something that needs updating? Suggest edits to this profile.